EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Studies on the vascular and hematological changes induced by ellagic acid in rats


Agents & Actions 22(3-4): 270-279
Studies on the vascular and hematological changes induced by ellagic acid in rats
We compared the major changes induced by ellagic acid (EA), a Hageman factor activator, in normal rats and in the kininogen-deficient Brown Norway rats. In normal rats, large doses of EA induced a congestion of lymph nodes, spleen and liver, a prolongation of activated partial thromboplastin time, the consumption of prekallikrein, high molecular weight kininogen and fibrinogen, as well as the stimulation of platelets with their accumulation in lungs, liver and spleen. A systemic hypotension of long duration was also observed. The fibrinogen consumption, the thrombocytopenia and the lengthening of inactivated partial thromboplastin time were dose-dependent. In kininogen-deficient rats, EA induced only a minimal congestion of lymphoid tissues. It is concluded that the vascular changes induced by blood coagulation with ellagic acid resulted mainly from kinin formation.

Accession: 006522935

PMID: 3445821

DOI: 10.1007/bf02009056

Download PDF Full Text: Studies on the vascular and hematological changes induced by ellagic acid in rats



Related references

Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats. Journal of Controlled Release 118(1): 27-37, 2007

Ellagic acid inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and prevents atheroma formation in streptozotocin-induced diabetic rats. Journal of Nutritional Biochemistry 24(11): 1830-1839, 2014

Some cardiovascular and hematological changes induced in the rat by activation of Hageman factor with ellagic acid. Advances in Experimental Medicine and Biology 247a: 461-465, 1989

Protective efficacy of ellagic acid on glycoproteins, hematological parameters, biochemical changes, and electrolytes in myocardial infarcted rats. Journal of Biochemical and Molecular Toxicology 26(7): 270-275, 2012

The effects of ellagic acid and 13-cis-retinoic acid on N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats. Cancer Letters 56(2): 117-124, 1991

The effects of ellagic acid and 13 cis retinoic acid alone and in combination on n nitrosobenzylmethylamine induced esophageal tumors in rats. Proceedings of the American Association for Cancer Research Annual Meeting 31: 120, 1990

Ellagic acid and the pulping of Eucalypts. Part I. Some aspects of the chemistry of ellagic acid. Part II. Complexes of ellagic acid with cations and solvents. Holzforschung, Berlin. 19: 4, 97-105, 1965

Inhibition of methylbenzylnitrosamine induced esophageal tumors in rats by ellagic acid. Proceedings of the American Association for Cancer Research Annual Meeting 27: 124, 1986

Inhibition of N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats by ellagic acid. Carcinogenesis 11(1): 55-61, 1990

Mechanism of the congestion of lymph nodes induced by ellagic acid in rats. Agents & Actions 22(3-4): 202-208, 1987